difluoromethylornithine


Also found in: Acronyms.

difluoromethylornithine

eflornithine hydrochloride.
References in periodicals archive ?
Randomized Prospective Phase III trial of Difluoromethylornithine vs Placebo in Preventing Recurrence of Completely Resected Low Risk Superficial Bladder Cancer.
Effect of dietary Extrato de cha verde green tea extract descafeinado, DFMO, and aerosolized analise da difluoromethylornithine concentracao de during lung tumor epigalocatequina, progression in A/J exame strain mice histopatologico, (Anderson e analise estatistica.
Cells were grown to confluence at which point they were treated with difluoromethylornithine (DFMO), diethylglyoxal bisguanylhydrazone (DEGBG), or a combination of the two.
Agent PK PD (IEB) Antiestrogens Tamoxifen +3 +4 (ER) Raloxifene +4 +4 (ER) Flutamide +2 +4 (AR) NSAI Ds Sulindac +3 +4 (Cox-1/2) R-Flurbiprofen +3 +4 (Cox-1/2) Retinoids 4-HPR +4 +4 (IGF-1, apoptosis) 9-cis-RA +4 +4 (RAR/RXR) 13-cis-RA +4 +4 (RAR/all-trans-RA) Selenium Se-methionine +3 +4 (GSH peroxidase) Dehydroepiandrosterone +4 +4 (Androgenic, estrogenic) Difluoromethylornithine +1 +4 (Polyamines) Agent Issue Antiestrogens Tamoxifen Endometrial CA (+) Raloxifene Endometrial (CA (-) Flutamide Gynecomastia NSAI Ds Sulindac GI toxicity R-Flurbiprofen R > S (anti-CA) Retinoids 4-HPR Night blindness (retinol concns.
Difluoromethylornithine, a drug to stop the growth of metastases, severely reduces platelet counts in the blood of cancer patients.
professor of medicine and biological chemistry at the University of California, Irvine, presented "late-breaking" results from a phase III trial of difluoromethylornithine (DFMO), a synthetic inhibitor of ornithine decarboxylase, and sulindac (Clinoril), a nonsteroidal, anti-inflammatory drug (NSAID), in 375 patients.
Currently under investigation are epigallocatechin gallate, a green tea catechin with antioxidant, sunscreen, and UVB signal transduction-blocking activity; perillyl alcohol, a monoterpene derived from citrus peel that inhibits Ras farnesylation; difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase and polyamines; retinoids that target retinoid X receptors and AP-1 activity; and nonsteroidal anti-inflammatory agents that inhibit cyclooxygenase and prostaglandin synthesis.